AzTrials
AzTrials

Chronic Kidney DiseasesNCT06458322

Quality of Life in Patients Transitioning to Home or In-Center Dialysis (QUALIFY CKD-to-HOME)

An observational study of Chronic Kidney Diseases, run by Ciusss de L'Est de l'Île de Montréal at 1 site in Canada.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The goal of this study is to evaluate quality of life (QoL) and frailty trajectories from advanced chronic kidney disease (CKD) to after dialysis initiation, specifically comparing patients choosing home dialysis and in-center hemodialysis. The main questions it aims to answer are: 1. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Chronic Kidney Diseases
What is being tested?
Home dialysis or In-Center dialysis
How many people
200 participants
Where
1 siteCanada
Study dates
1 Jul 2022to 31 Dec 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Adults followed in advanced chronic kidney disease clinics recruited from 7 centers across Canada

Who may be able to join

  • Adult patients followed in advanced CKD clinic;
  • eGFR ≤12 mL/min/1.73m2 96;
  • Understand English or French.

Who cannot join

  • Orientation toward conservative treatment;
  • Planned kidney transplantation < 6 months;
  • Unable to provide consent due to severe cognitive or psychiatric disease;
  • Previous treatment with dialysis > 3 month;
  • Life expectancy < 6 months.

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Canada1 site, 1 recruiting
  • Hôpital Maisonneuve-Rosemont

    Montreal, Quebec, H1T 2M4

    Annie-Claire Nadeau-Fredette, MD, 514-252-3400 ext. 6141, ac.nadeau-fredette@umontreal.ca

    Karine Chaussé, 514-242-3400 ext. 3722, karine.chausse.cemtl@ssss.gouv.qc.ca

    Recruiting

Other trials in Canada

About this study

Official title: Prospective Changes in Quality of Life and Frailty in Chronic Kidney Disease Patients Transitioning to Home Versus In-Center Dialysis (QUALIFY CKD-to-HOME Study)

The goal of this study is to evaluate quality of life (QoL) and frailty trajectories from advanced chronic kidney disease (CKD) to after dialysis initiation, specifically comparing patients choosing home dialysis and in-center hemodialysis.

The main questions it aims to answer are:

Read more
  1. What is the trajectory of QoL in patients transitioning from advanced CKD to dialysis (up to 12 months after initiation) and how does these changes differ for patients oriented towards home dialysis and in-center hemodialysis?
  2. Is the development of frailty after dialysis initiation less likely in patient pursuing home dialysis?
  3. What is the variation in other PROMs and health outcomes (fatigue, anxiety \& depression, general assessment, cognitive function) form advanced CKD to the first 12 months after dialysis initiation?
  4. What are the predictors of severe decline in QoL, frailty and other important health outcomes (fatigue, cognition, anxiety \& depression) during CKD G5 follow-up and after 12 months post dialysis initiation?

Participants will be ask to:

  • Answer some questions and complete questionnaires each 3 months;
  • Do a a grip test and a walking test each 6 months to evaluate their frailty;
Read the detailed description

Background. Home dialysis is encouraged as the preferred therapy for people starting dialysis across Canada, with increased use of peritoneal dialysis (PD) and home hemodialysis (HHD) for patients with higher comorbidity burden. Dialysis modality selection is primarily a patient-centered choice. Modality selection should be mostly based on lifestyle and personal values. Despite the recognition of this patient-centered decision, most dialysis modality studies are based on mortality, hospitalization, and socioeconomic factors. There is a paucity of data to best inform patients of the expected changes in patient-reported outcomes measures (PROMs) such as quality of life (QoL), and the progression of their frailty status after dialysis initiation.

Objective. This study will fill this knowledge gap and evaluate QoL and frailty trajectories from advanced chronic kidney disease (CKD) to after dialysis initiation, specifically comparing patients choosing home dialysis and in-center hemodialysis (ICHD).

Design and Research Plan. Qualify CKD-to-Home is a prospective cohort study in 7 centers across Canada, with active patient-partner engagement. It is expected that around 200 patients will participate. Effort will be made to keep the ration of patients oriented towards home dialysis versus in-center at 1:2 or less.

Every 3 months participants will be followed, from estimated glomerular filtration rate (eGFR) <12 mL/min/1.73m2 and up to 12 months after dialysis start. They will be ask to complete questionnaires as the Kidney Disease Quality of Life (KDQOL-36), Quality of Life, the Hospital Anxiety and Depression Scale (HADS), the Standardized outcomes in Nephrology (SONG)-HD, Fatigue, the Medical Outcome Study- Social Support Survey (MOS-SSS), Social Support, the Montreal Cognitive assessment (MoCa), Cognitive Function, the Clinical Frailty Scale (CFS), the Fried Frailty Phenotype (FP) and the Gender-Related Variable for Health Research questionnaire (GVHR).

Analyse. Descriptive statistics will be used to report baseline characteristics for all patients. The KDQOL-36 components and domains, CFS, FI, HADS, SONG Fatigue instrument, feeling thermometer and MOCA, will be treated as continuous measures. Relationship between baseline scores will be assessed using Spearman correlation. Within patient changes in QoL, continuous frailty measures (CFS, FI), fatigue, depression \& anxiety and general health will be described using generalized linear mixed effects models for repeated measures over time. Within patient changes in the proportion of patients classified as frail (vs. non-frail \& pre-frail) using the FP with dichotomization will be analyzed in generalized linear mixed models with logistic links for binary repeated measures outcomes nested within centers. Missing data will be managed using multiple imputation by chained equations prior to proposed analyses.

Future directions. This study will help inform patients with advanced CKD on the trajectory of important patient-centered outcomes after dialysis initiation with different dialysis modality. Data from this study will be used to build on a mixed-methods approach with qualitative interviews of patients / caregiver to extend the reach of our understanding on PROMs (QoL) and frailty changes during the CKD to dialysis transition. Finally, the study results will guide stakeholders in the development of interventions that will mitigate risk of adverse outcomes for home dialysis patients at increased risk, as identified in our study.

Being tested
Home dialysis or In-Center dialysis
Keywords
Chronic Kidney Diseases, Quality of Life, Frailty, Dialysis, Home dialysis, In-center dialysis, Peritoneal dialysis, Home hemodialysis, Hemodialysis
Medical subject headings
Renal Insufficiency, Chronic, Frailty

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Home dialysis or In-Center dialysisOther

    Initiation of dialysis with home dialysis (peritoneal dialysis or home hemodialysis) or in-center dialysis (hemodialysis)

Study groups in NCT06458322
Study groupRoleWhat they receive
Home dialysis modalityParticipants that determined peritoneal dialysis or home hemodialysis as their modality of treatment.
Receives: Other: Home dialysis or In-Center dialysis
In-center dialysis modalityParticipants that determined in-center hemodialysis as their modality of treatment.
Receives: Other: Home dialysis or In-Center dialysis

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Kidney Disease Quality of Life - 36

    Patients Scale from 0-100 (0 = poor, 100 = excellent).

    Measured: From study inclusion until 12-months after dialysis start.

Secondary outcomes (5)
  1. Change in Fried Frailty phenotype

    5 components (slowness, weakness, weight loss, low physical activity, exhaustion) with classification as no-frail, pre-frail or frail.

    Measured: From study inclusion until 12-months after dialysis start.

  2. Change in Clinical Frailty Scale

    Scale 1 (very fit) to 9 (terminally ill)

    Measured: From study inclusion until 12-months after dialysis start

  3. Change in Hospital Anxiety and Depression

    14 items scale (7 anxiety, 7 depression) with score >8 as cut-off for increased risk of depression and anxiety.

    Measured: From study inclusion until 12-months after dialysis start

  4. Change in Fatigue

    3 items questionnaire to assess fatigue and energy.

    Measured: From study inclusion until 12-months after dialysis start

  5. Change in Cognitive Function (MoCa)

    8 cognitive domains: attention and concentration, executive functions, memory, language, visuo-constructional skills, conceptual thinking, calculations, and orientation with a possible score of 30 points.

    Measured: From study inclusion until 12-months after dialysis start

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted13 Jun 2024
  2. Study start1 Jul 2022
  3. Primary completion31 Dec 2027 (estimated)
  4. Study completion31 Dec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
200 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06458322
Sponsor's protocol ID
2022_2844
Status last verified
Feb 2026
First submitted
10 Jun 2024
Last updated
23 Feb 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Chronic Kidney Diseases, run by Ciusss de L'Est de l'Île de Montréal at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 23 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Émilie Robitaille, Bac Sc. Inf. (514-252-3400 ext. 5289, emilie.robitaille.cemtl@ssss.gouv.qc.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Kidney Disease Quality of Life - 36 (time frame: From study inclusion until 12-months after dialysis start.). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Feb 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in